Evidence map›Paper›PMID 22142152›Full record

ArticleExpert review of clinical pharmacology2012

Clinical pharmacology in neonates and young infants: the benefit of a population-tailored approach.

John van den Anker, Karel Allegaert

Abstract readEditorial
In one paragraph

Article in Expert review of clinical pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. USE OF OFF-LABEL MEDICATIONS IN A NEONATAL INTENSIVE CARE UNIT.Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2021
    Article
  3. Article
  4. Article
  5. Neuroprotective Strategies after Neonatal Hypoxic Ischemic Encephalopathy.International journal of molecular sciences · 2015
    Review
  6. Article
  7. Observational
  8. Neonates need tailored drug formulations.World journal of clinical pediatrics · 2013
    Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

John van den Anker
Karel Allegaert

Funding

Preclinical dosing optimization: Dosing schedule, tissueU54HD071601 · NICHD · CHILDREN'S RESEARCH INSTITUTE · PI VAN DEN ANKER, JOHN NICOLAAS · 2011 to 2015
$4.0M
Metabolism and Toxicity of Acetaminophen in Preterm InfantsR01HD060543 · NICHD · CHILDREN'S RESEARCH INSTITUTE · PI VAN DEN ANKER, JOHANNES NICOLAAS · 2010 to 2014
$1.5M
Optimizing the Use of Morphine in Preterm InfantsR01HD048689 · NICHD · CHILDREN'S NATIONAL MEDICAL CENTER · PI VAN DEN ANKER, JOHANNES NICOLAAS · 2005 to 2009
$1.5M
Optimizing the Use of Methadone in Newborn InfantsK24DA027992 · NIDA · CHILDREN'S RESEARCH INSTITUTE · PI VAN DEN ANKER, JOHANNES NICOLAAS · 2010 to 2014
$878k
NICHD NIH HHS R01 HD048689NICHD NIH HHS R01HD048689NICHD NIH HHS R01 HD060543NICHD NIH HHS R01HD060543NICHD NIH HHS U54 HD071601NICHD NIH HHS U54HD071601NIDA NIH HHS K24 DA027992NIDA NIH HHS K24DA027992
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

HumansInfantInfant, NewbornPharmacology, ClinicalPopulation SurveillanceRandomized Controlled Trials as Topic

Identifiers

PMID22142152
PMCPMC4709247

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.